摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

1-(tert-butoxycarbonyl)-4-[2,6-difluoro-4-(benzyloxycarbonyl)aminophenyl]piperazine

中文名称
——
中文别名
——
英文名称
1-(tert-butoxycarbonyl)-4-[2,6-difluoro-4-(benzyloxycarbonyl)aminophenyl]piperazine
英文别名
4-(4-benzyloxycarbonylamino-2,6-difluoro-phenyl)-piperazine-1-carboxylic acid tert-butyl ester;tert-butyl 4-[2,6-difluoro-4-(phenylmethoxycarbonylamino)phenyl]piperazine-1-carboxylate
1-(tert-butoxycarbonyl)-4-[2,6-difluoro-4-(benzyloxycarbonyl)aminophenyl]piperazine化学式
CAS
——
化学式
C23H27F2N3O4
mdl
——
分子量
447.482
InChiKey
FKFNQKOOYVUIIY-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    4
  • 重原子数:
    32
  • 可旋转键数:
    7
  • 环数:
    3.0
  • sp3杂化的碳原子比例:
    0.39
  • 拓扑面积:
    71.1
  • 氢给体数:
    1
  • 氢受体数:
    7

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

点击查看最新优质反应信息

文献信息

  • Esters of substituted-hydroxyacetyl piperazine phenyl oxazolidinones
    申请人:Pharmacia & Upjohn Company
    公开号:US05652238A1
    公开(公告)日:1997-07-29
    A compound of structural Formula (I) or pharmaceutically acceptable salts thereof wherein: R is --C(O)--R.sup.1, --PO.sub.3 .dbd. or --P(O)(OH).sub.2 ; R.sup.1 is C.sub.1-6 alkyl, --N(R.sup.4).sub.2, C.sub.1-6 alkyl-N(R.sup.4).sub.2, --phenyl--N(R.sup.4).sub.2, --phenyl-NHC(O)CH.sub.2 NH.sub.2, --C.sub.2 H.sub.4 -morpholinyl, pyridinyl, C.sub.1-6 alkyl-OH, C.sub.1-6 alkyl-OCH.sub.3, C.sub.1-6 alkyl C(O)CH.sub.3, --O--C.sub.1-6 alkyl-OCH.sub.3, C.sub.0-3 alkyl-piperazinyl (optionally substituted with C.sub.1-3 alkyl), imidazolyl, C.sub.1-6 alkyl-COOH, --C(CH.sub.2 OH).sub.2 CH.sub.3 ; R.sup.2 and R.sup.3 are independently selected from hydrogen or F except at least one of R.sup.2 or R.sup.3 is F; R.sup.4 are independently selected from hydrogen or C.sub.1-6 alkyl. The compounds are water soluble and are useful antimicrobial agents, effective against a number of human veterinary pathogens, including multiply-resistant staphylococci, enterococci and streptococci, as well as anerobic organisms such as bacteroides and clostridia species, and acid-fast organisms such as Mycobacterium tuberculosis.
    结构式(I)的化合物或其药用盐,其中:R为--C(O)--R.sup.1,--PO.sub.3 .dbd.或--P(O)(OH).sub.2;R.sup.1为C.sub.1-6烷基,--N(R.sup.4).sub.2,C.sub.1-6烷基-N(R.sup.4).sub.2,--苯基--N(R.sup.4).sub.2,--苯基-NHC(O)CH.sub.2 NH.sub.2,--C.sub.2 H.sub.4 -吗啉基,吡啶基,C.sub.1-6烷基-OH,C.sub.1-6烷基-OCH.sub.3,C.sub.1-6烷基C(O)CH.sub.3,--O--C.sub.1-6烷基-OCH.sub.3,C.sub.0-3烷基-哌嗪基(可选择性地取代为C.sub.1-3烷基),咪唑基,C.sub.1-6烷基-COOH,--C(CH.sub.2 OH).sub.2 CH.sub.3;R.sup.2和R.sup.3分别选择自氢或F,除非R.sup.2或R.sup.3中至少有一个为F;R.sup.4独立选择自氢或C.sub.1-6烷基。这些化合物可溶于水,是有用的抗菌剂,对多种人兽共患病原体具有有效作用,包括多重耐药葡萄球菌、肠球菌和链球菌,以及厌氧生物如拟杆菌和梭菌属,以及耐酸生物如结核分枝杆菌。
  • Oxazolidinone antimicrobials containing substituted diazine moieties
    申请人:The Upjohn Company
    公开号:US05547950A1
    公开(公告)日:1996-08-20
    A compound of structural Formula I: ##STR1## or pharmaceutically acceptable salts thereof wherein: each n is independently 1 to 3; Y is chosen from a-n as defined herein; wherein each occurrence of said C.sub.1-6 alkyl may be substituted with one or more F, Cl, Br, I, OR.sup.1, CO.sub.2 R.sup.1, CN, SR.sup.1, or R.sup.1 (where R.sup.1 is a hydrogen or C.sub.1-4 alkyl); X and Z are independently C.sub.1-6 alkyl, C.sub.3-12 cycloalkyl or hydrogen, or X and Z form a C.sub.0-3 bridging group, preferably X and Z are hydrogen; U, V and W are independently C.sub.1-6 alkyl, F, Cl, Br, hydrogen or a C.sub.1-6 alkyl substituted with one or more of F, Cl, Br or I, preferably U and V are F and W is hydrogen; R is hydrogen, C.sub.1-12 alkyl, C.sub.3-12 cycloalkyl, C.sub.1-6 alkoxy, C.sub.1-6 alkyl substituted with one or more F, Cl, Br, I or OH; and q is 0 to 4 inclusive. Oxazolidinone derivatives possessing a substituted diazine moiety bonded to the N-aryl ring are useful antimicrobial agents, effective against a number of human and veterinary pathogens, including multiply-resistant staphylococci and streptococci, as well as anaerobic organisms such as bacteroides and clostridia species, and acid-fast organisms such as Mycobacterium tuberculosis and Mycobacterium avium.
    结构式I的化合物:##STR1##或其药用可接受的盐,其中:每个n独立地为1到3;Y从a-n中选择,如此处所定义;其中所述的每个C.sub.1-6烷基的每次出现可以用一个或多个F、Cl、Br、I、OR.sup.1、CO.sub.2R.sup.1、CN、SR.sup.1或R.sup.1(其中R.sup.1是氢或C.sub.1-4烷基)替代;X和Z独立地为C.sub.1-6烷基、C.sub.3-12环烷基或氢,或X和Z形成一个C.sub.0-3桥联基,优选X和Z为氢;U、V和W独立地为C.sub.1-6烷基、F、Cl、Br、氢或一个或多个F、Cl、Br或I取代的C.sub.1-6烷基,优选U和V为F,W为氢;R为氢、C.sub.1-12烷基、C.sub.3-12环烷基、C.sub.1-6烷氧基、一个或多个F、Cl、Br、I或OH取代的C.sub.1-6烷基;q为0到4(包括4)。具有与N-芳基环结合的取代二嗪基团的噁唑烷酮衍生物是有用的抗微生物药剂,对许多人类和兽医病原体有效,包括多重耐药葡萄球菌和链球菌,以及厌氧生物,如拟杆菌和梭菌属,以及耐酸生物,如结核分枝杆菌和分枝杆菌。
  • NOVEL ANTIMICROBIALS
    申请人:Jain Rajesh
    公开号:US20110245258A1
    公开(公告)日:2011-10-06
    The present invention relates to novel phenyl oxazolidinone compounds of formula I, their pharmaceutically acceptable analogs, tautomeric forms, stereoisomers, polymorphs, prodrugs, metabolites, salts or solvates thereof. The invention also relates to the processes for the synthesis of novel compounds of formula I or their pharmaceutically acceptable analogs, tautomeric forms, stereoisomers, polymorphs, prodrugs, metabolites, salts or solvates thereof. The present invention also provides pharmaceutical compositions comprising novel compounds of formula I and methods of using them. The compounds of the present invention are useful as antimicrobial agents, effective against a number of aerobic and/or anaerobic Gram positive and/or Gram negative pathogens such as multi drug resistant species of Staphylococcus, Streptococcus, Enterococcus, Bacterioides, Clostridia, H. influenza, Moraxella, acid-fast organisms such as Mycobacterium tuberculosis as well as Linezolid resistant species of Staphylococcus and Enterococcus.
    本发明涉及公式I的新型苯基噁唑啉酮化合物,它们的药学上可接受的类似物、互变异构体、立体异构体、多晶形态、前药、代谢物、盐或其溶剂。本发明还涉及合成公式I的新化合物或其药学上可接受的类似物、互变异构体、立体异构体、多晶形态、前药、代谢物、盐或其溶剂的过程。本发明还提供了包含公式I的新化合物的制药组合物和使用它们的方法。本发明的化合物是抗微生物剂,对多种需氧和/或厌氧革兰阳性和/或革兰阴性病原体具有有效作用,如金黄色葡萄球菌、链球菌、肠球菌、拟杆菌、梭菌、流感嗜血杆菌、摩拉克斯氏菌、抗利多霉素的金黄色葡萄球菌和肠球菌等耐药菌。
  • Antimicrobials
    申请人:Jain Rajesh
    公开号:US08841306B2
    公开(公告)日:2014-09-23
    The present invention relates to novel phenyl oxazolidinone compounds of formula I, their pharmaceutically acceptable analogs, tautomeric forms, stereoisomers, polymorphs, prodrugs, metabolites, salts or solvates thereof. The invention also relates to the processes for the synthesis of novel compounds of formula I or their pharmaceutically acceptable analogs, tautomeric forms, stereoisomers, polymorphs, prodrugs, metabolites, salts or solvates thereof. The present invention also provides pharmaceutical compositions comprising novel compounds of formula I and methods of using them. The compounds of the present invention are useful as antimicrobial agents, effective against a number of aerobic and/or anaerobic Gram positive and/or Gram negative pathogens such as multi drug resistant species of Staphylococcus, Streptococcus, Enterococcus, Bacterioides, Clostridia, H. influenza, Moraxella, acid-fast organisms such as Mycobacterium tuberculosis as well as Linezolid resistant species of Staphylococcus and Enterococcus.
    本发明涉及公式I的新型苯基噁唑啉酮化合物,它们的药学上可接受的类似物、互变异构体、立体异构体、多晶形态、前药、代谢物、盐或其溶剂。本发明还涉及制备公式I的新化合物或其药学上可接受的类似物、互变异构体、立体异构体、多晶形态、前药、代谢物、盐或其溶剂的方法。本发明还提供了包括公式I的新化合物的制药组合物和使用它们的方法。本发明的化合物可作为抗微生物剂使用,对多种革兰氏阳性和/或革兰氏阴性病原体具有有效作用,如耐多种药物的金黄色葡萄球菌、链球菌、肠球菌、拟杆菌、梭菌、流感嗜血杆菌、摩拉克斯菌、酸性快速菌如结核分枝杆菌,以及对利奈唑胺耐药的金黄色葡萄球菌和肠球菌。
  • OXAZOLIDINONES CONTAINING A SUBSTITUTED DIAZINE MOIETY AND THEIR USE AS ANTIMICROBIALS
    申请人:PHARMACIA & UPJOHN COMPANY
    公开号:EP0640077B1
    公开(公告)日:2002-06-26
查看更多